FDA rejects Regenxbio's gene therapy in Hunter syndrome, leaving CEO 'concerned' - Fierce Biotech
After facing a delayed decision deadline and a clinical hold, Regenxbio’s Hunter syndrome gene therapy has been rejected by the FDA. | After facing a delayed decision deadline and a clinical hold, Regenxbio’s Hunter syndrome gene therapy has been rejected by …
Comments